Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;38:1388-1394
doi: 10.1161/hy1201.098768
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frohlich, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frohlich, E. D.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*High Blood Pressure

(Hypertension. 2001;38:1388.)
© 2001 American Heart Association, Inc.


Fourth International Seminar on Cardiovascular Biology and Medicine: Part II

Local Hemodynamic Changes in Hypertension

Insights for Therapeutic Preservation of Target Organs

Edward D. Frohlich

From the Alton Ochsner Medical Foundation, New Orleans, La.

Correspondence to Edward D. Frohlich, MD, Alton Ochsner Distinguished Scientist, Alton Ochsner Medical Foundation, 1516 Jefferson Hwy, New Orleans, LA 70121.

Abstract

As a result of antihypertensive therapy, there has been a remarkable decrease in morbidity and mortality from such cardiovascular endpoints as stroke, coronary heart disease, and major hypertensive emergencies. In contrast, there has been no relenting in the increasing prevalence of cardiac failure and end-stage renal disease (ESRD) associated with hypertensive cardiovascular disease. Recent experience in our laboratories that involved the natural development of the cardiac and renal hemodynamic alterations in spontaneously hypertensive rats demonstrated that the natural history and pathophysiological lesions associated with cardiac failure and ESRD may be vastly different from the heretofore more pressure-dependent brain and other cardiac endpoints reported in earlier years. These initial antihypertensive agents (eg, diuretics, ß-adrenergic receptor inhibitors) had minimal anti-ischemic and antifibrotic effects on heart and kidney and did not exert the cardiac and nephroprotective hemodynamic effects of the newer classes of agents. The cardiac and renal endpoints resulting in organ failure today are more related to ischemia, intraorgan fibrosis, and aging. Our experimental studies summarized herein strongly suggest that the newer classes of antihypertensive drugs (ie, ACE inhibitors, angiotensin II type 1 receptor antagonists, certain calcium antagonists, and perhaps L-arginine) may reverse these pathophysiological lesions through improving blood flow and flow reserve, their antifibrotic and other actions. To this end, we look forward to the results of ongoing, well-controlled, and prospectively conducted multicenter clinical studies designed to demonstrate prevention of cardiac and renal failure.


Key Words: rats, spontaneously hypertensive • ventricular ischemia • ventricular fibrosis • renal ischemia • renal failure • angiotensin-converting enzyme inhibitors • AT1 receptor blockade • calcium antagonists




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
S. Gao, C.-L. Long, R.-H. Wang, and H. Wang
KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function
Cardiovasc Res, August 1, 2009; 83(3): 444 - 456.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Susic, J. Varagic, J. Ahn, L. Matavelli, and E. D. Frohlich
Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H175 - H179.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz
Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H684 - H691.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. G. Carlier and D. Bertoldi
In vivo functional NMR imaging of resistance artery control
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1028 - H1036.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
X. Zhou and E. D. Frohlich
Ageing, hypertension and the kidney: new data on an old problem
Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1442 - 1445.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
X. Zhou and E. D. Frohlich
Ageing, hypertension and the kidney: new data on an old problem
Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1442 - 1445.
[Full Text]